6:18 PM
 | 
Jan 02, 2013
 |  BC Extra  |  Clinical News

Synergy jumps on plecanatide constipation data

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) added $0.95 (18%) to $6.21 on Wednesday after once-daily 3 mg oral plecanatide met the primary endpoint in the Phase...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >